Trans-Activator Of Transcription (Tat) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Trans-Activator Of Transcription (Tat) - Pipeline Review, H1 2016

Trans-Activator Of Transcription (Tat) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Trans-Activator Of Transcription (Tat) - Pipeline Review, H1 2016
Published Jun 30, 2016
43 pages — Published Jun 30, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Trans-Activator Of Transcription (Tat) - Pipeline Review, H1 2016, provides in depth analysis on Trans-Activator Of Transcription (Tat) targeted pipeline therapeutics.

The report provides comprehensive information on the Trans-Activator Of Transcription (Tat), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Trans-Activator Of Transcription (Tat) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Trans-Activator Of Transcription (Tat)
- The report reviews Trans-Activator Of Transcription (Tat) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Trans-Activator Of Transcription (Tat) targeted therapeutics and enlists all their major and minor projects
- The report assesses Trans-Activator Of Transcription (Tat) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Trans-Activator Of Transcription (Tat) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Trans-Activator Of Transcription (Tat)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by un

  
Source:
Document ID
GMDHC0325TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Trans-Activator Of Transcription (Tat) Overview61
Therapeutics Development73
  Trans-Activator Of Transcription (Tat) Products under Development by Stage of Development71
  Trans-Activator Of Transcription (Tat) Products under Development by Therapy Area81
  Trans-Activator Of Transcription (Tat) Products under Development by Indication91
Trans-Activator Of Transcription (Tat) Pipeline Products Glance102
  Late Stage Products101
  Early Stage Products111
Trans-Activator Of Transcription (Tat) Products under Development by Companies122
Trans-Activator Of Transcription (Tat) Products under Development by Universities/Institutes142
Trans-Activator Of Transcription (Tat) Therapeutics Assessment166
  Assessment by Monotherapy/Combination Products161
  Assessment by Mechanism of Action171
  Assessment by Route of Administration182
  Assessment by Molecule Type202
Trans-Activator Of Transcription (Tat) Companies Involved in Therapeutics Development222
  Akshaya Bio Inc.221
  Biosantech SA231
Trans-Activator Of Transcription (Tat) Drug Profiles249
  CSTATI-1 Drug Profile242
  HIV vaccine Drug Profile262
  HIV vaccine Drug Profile281
  HIV vaccine Drug Profile291
  HIV-1 vaccine Drug Profile302
  Recombinant Protein to Inhibit Tat and Rev for HIV-1 Drug Profile321
Trans-Activator Of Transcription (Tat) Dormant Projects331
Trans-Activator Of Transcription (Tat) Discontinued Products341
Trans-Activator Of Transcription (Tat) Featured News &Press Releases357
  Jun 08, 2016: Improving the Effect of HIV Drugs by Use of the Tat Vaccine351
  Mar 15, 2016: Publication in Retrovirology of the results of Biosantech's phase IIA clinical trial for the anti-HIV candidate vaccine361
  Jul 29, 2015: Cannabis Science Signs Gary Blick, MD and Proceeds With CS-TATI-1 for HIV and Kaposi Sarcoma Drug Development Program361
  Jan 02, 2015: HIV vaccines should avoid viral target cells, primate model study suggests371
  Apr 26, 2013: Cannabis Science Announces Preclinical Development Program For CS-TATI-I381
  Nov 12, 2012: Beth Israel Deaconess Medical Center, Harvard Medical School Study Confirms Cannabis Science's Approach To Development Of CS-TATI-1 To Inhibit Kaposi Sarcoma391
  Sep 24, 2012: Cannabis Science Initiates Preclinical Investigation Of CS-TATI-1 For European Studies For Squamous/Basal Cell Carcinomas And Kaposi s Sarcoma401
  Aug 13, 2012: CBIS Initiates GMP Development Plan For CS-TATI-1411
Appendix422
  Methodology421
  Coverage421
  Secondary Research421
  Primary Research421
  Expert Panel Validation421
  Contact Us421
  Disclaimer431

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Trans-Activator Of Transcription (Tat) - Pipeline Review, H1 2016" Jun 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Trans-Activator-Of-Transcription-Tat-Pipeline-Review-H1-2016-2088-16145>
  
APA:
Global Markets Direct - Market Research. (2016). Trans-Activator Of Transcription (Tat) - Pipeline Review, H1 2016 Jun 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Trans-Activator-Of-Transcription-Tat-Pipeline-Review-H1-2016-2088-16145>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.